ICU Medical, Inc. (NASDAQ:ICUI – Get Free Report) shares were up 10.2% during trading on Tuesday . The stock traded as high as $95.97 and last traded at $95.75. Approximately 158,014 shares traded hands during mid-day trading, a decline of 36% from the average daily volume of 246,068 shares. The stock had previously closed at $86.88.
Analyst Ratings Changes
A number of analysts recently weighed in on ICUI shares. KeyCorp initiated coverage on shares of ICU Medical in a report on Tuesday. They issued an “overweight” rating and a $134.00 price objective on the stock. TheStreet lowered ICU Medical from a “c-” rating to a “d+” rating in a research report on Tuesday, October 10th. Finally, CL King began coverage on shares of ICU Medical in a research note on Thursday, December 14th. They set a “buy” rating and a $110.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $122.00.
ICU Medical Stock Up 9.3 %
The company has a quick ratio of 0.99, a current ratio of 2.63 and a debt-to-equity ratio of 0.76. The business has a 50-day simple moving average of $94.26 and a 200-day simple moving average of $113.21. The stock has a market cap of $2.29 billion, a P/E ratio of -79.52 and a beta of 0.65.
ICU Medical (NASDAQ:ICUI – Get Free Report) last posted its quarterly earnings data on Monday, November 6th. The medical instruments supplier reported $1.23 EPS for the quarter, topping analysts’ consensus estimates of $0.94 by $0.29. ICU Medical had a positive return on equity of 6.53% and a negative net margin of 1.25%. The business had revenue of $553.31 million for the quarter, compared to analyst estimates of $554.00 million. Analysts expect that ICU Medical, Inc. will post 5.07 EPS for the current year.
Insider Transactions at ICU Medical
In other news, VP Daniel Woolson sold 1,729 shares of ICU Medical stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $88.03, for a total transaction of $152,203.87. Following the sale, the vice president now owns 9,877 shares of the company’s stock, valued at approximately $869,472.31. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 7.50% of the company’s stock.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in ICUI. Covestor Ltd raised its position in ICU Medical by 86.4% during the first quarter. Covestor Ltd now owns 123 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 57 shares in the last quarter. Captrust Financial Advisors raised its stake in ICU Medical by 4.5% in the 2nd quarter. Captrust Financial Advisors now owns 1,327 shares of the medical instruments supplier’s stock valued at $218,000 after acquiring an additional 57 shares during the period. Osaic Holdings Inc. lifted its holdings in ICU Medical by 8.9% during the 2nd quarter. Osaic Holdings Inc. now owns 1,012 shares of the medical instruments supplier’s stock valued at $180,000 after purchasing an additional 83 shares during the last quarter. First Republic Investment Management Inc. lifted its stake in shares of ICU Medical by 7.6% during the 1st quarter. First Republic Investment Management Inc. now owns 1,438 shares of the medical instruments supplier’s stock worth $237,000 after buying an additional 102 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its holdings in shares of ICU Medical by 4.1% during the second quarter. Wells Fargo & Company MN now owns 2,722 shares of the medical instruments supplier’s stock worth $485,000 after acquiring an additional 106 shares during the period. 91.49% of the stock is owned by institutional investors.
ICU Medical Company Profile
ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; and ClearGuard HD, that maintains hemodialysis catheters.